Phase 4 N=30 Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
Blepharitis
Primary: Improvement in Signs and Symptoms of Blepharitis — 15; 15 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=231 Using Virtual Reality to Train Children in Pedestrian Safety
Street-crossing Ability · Pedestrian Safety
Primary: Street-crossing Ability — 2.7; 2.3; 2.6; 3.0 number of hits/close calls — p=<0.05
N/A N=105 Mobile Communication Technology for Adolescents With Diabetes
Type 1 Diabetes
Primary: Quality of Parent-child Relationship — 0.22; -3.24; -0.59 units on a scale
Phase 2 N=25 Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
Asthma
Primary: Cmax of Budesonide After Administration of MAP0020 — 92.5; 175; 370 pg/ml
N/A N=84 Clinical Evaluation of the OrthoPAT Advance System
Transmission, Blood, Recipient/Donor
Primary: Washed RBC Hematocrit — 55.43; 56.48 percentage of HcT
Phase 3 N=4 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Cushing's Disease · Cushing's Syndrome
Primary: Number of Participants With Adverse Events — 4 participants
N/A N=64 Lifting and Tightening of the Face and Neck Utilizing the Ulthera® System
Facial and Neck Skin Laxity
Primary: Improvement in Overall Lifting and Tightening of the Jowls and/or Neck Laxity — 22; 10; 1; 11 participants
Phase 2 N=369 A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
Influenza Caused by the Novel Influenza A (H1N1) Virus
Primary: Haemagglutination Inhibition (HI) Antibody Titre Seroconversion Rate After the First Vaccination — 88.2; 97.3; 85.7; 91.9 percentage of participants
N/A N=2,430 Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1) — 685 participants
Phase 4 N=33 A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission
Arthritis, Rheumatoid
Primary: Percentage of Participants in Remission at Week 28 — 87.5; 18.8 percentage of participants
Phase 4 N=42 Promiseb Topical Cream for Cradle Cap
Cradle Cap · Infantile Seborrheic Dermatitis
Primary: Subjects With Investigator Global Assessment (IGA) Success (IGA of 0 or 1) at End of Treatment (Day 7 or 14). — 91.7; 96 percentage of participants — p=>0.05
Phase 2 N=40 Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Gastric Cancer
Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants
Phase 4 N=506 A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
Pneumococcal Infections
Primary: Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar — 6.90; 7.16; 7.53; 9.45 μg/mL
Phase 2 N=60 Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: 6 Month Progression-free Survival (PFS) — 13 participants
Phase 2 N=86 Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1
Opioid-Related Disorders
Primary: SOWS: the Subjective Opiate Withdrawal Scale — 11.5; 12.5 units on a scale